该公司2024年全年收入预计略低，为1.227亿美元。这一调整与竞争加剧可能对Assertio前主打产品Indocin的影响有关。尽管面临挑战，Assertio有效维持了Indocin的市场份额，H.C. Wainwright维持Assertio股票的买入评级，目标价格稳定在4.00美元。 公司整体毛利率有所提高 ...

The adjustment is attributed to the potential impact of increased competition on the company's former top product, Indocin. Despite challenges, Assertio has successfully defended its market share for ...

The adjustment is attributed to the potential impact of increased competition on the company's former top product, Indocin. Despite challenges, Assertio has successfully defended its market share ...

The company has managed to preserve its market share with Indocin, maintaining robust gross margins above 90%. Additionally, the recent financial results showed a better-than-expected bottom line ...